Literature DB >> 10602435

Analysis of p73 and p53 gene deletions in multiple myeloma.

B Schultheis1, A Krämer, A Willer, U Hegenbart, H Goldschmidt, R Hehlmann.   

Abstract

Recently, p73, a protein with structural and functional similarities to p53, an extensively studied tumor suppressor gene, has been cloned. After being mapped to the chromosomal region 1p35-1p36, it has been postulated to act as a tumor suppressor gene, too, as this region is altered in several human malignancies. Deletions of the short arm of chromosome 1 have frequently been described in multiple myeloma (MM) whereas structural abnormalities of the 17p13 region including p53 are rare events in this disease. Since it has been proposed that especially neoplasias lacking p53 alterations might show a loss of heterozygosity at 1p35-1p36, we studied the frequency of p53 and p73 deletions in bone marrow mononuclear cells of 68 patients with MM, two patients with monoclonal gammopathy of undetermined significance and four patients with plasma cell leukemia. Dual-color fluorescence in situ hybridization (FISH) for p53 and p73 was performed using commercially available DNA probes for 17p13.3 and the microsatellite marker D1Z2, respectively. Centromeric DNA probes served to distinguish gene deletions from whole chromosome losses. In contrast to recently published FISH results, we only detected heterozygous p53 deletions in eight out of the 74 patients, three of them showing a monosomy 17. Heterozygous deletions of the D1Z2 region at 1p36 were found in six cases with one patient having a monosomy 1. Neither homozygous deletions of either chromosomal region nor nullisomies 1 or 17 could be detected. These results argue against a major role of p73 deletions in MM. As MM patients with 1p structural abnormalities have a significantly poorer survival rate than those with normal karyotypes, the role of other putative tumor suppressor genes located at the chromosomal region 1p36 in the pathogenesis of MM has to be determined.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10602435     DOI: 10.1038/sj.leu.2401609

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  8 in total

1.  Impact of acquired del(17p) in multiple myeloma.

Authors:  Arjun Lakshman; Utkarsh Painuly; S Vincent Rajkumar; Rhett P Ketterling; Prashant Kapoor; Patricia T Greipp; Angela Dispenzieri; Morie A Gertz; Francis K Buadi; Martha Q Lacy; David Dingli; Amie L Fonder; Suzanne R Hayman; Miriam A Hobbs; Wilson I Gonsalves; Yi Lisa Hwa; Nelson Leung; Ronald S Go; Yi Lin; Taxiarchis V Kourelis; Rahma Warsame; John A Lust; Stephen J Russell; Steven R Zeldenrust; Robert A Kyle; Shaji K Kumar
Journal:  Blood Adv       Date:  2019-07-09

2.  Genetic aberrations and survival in plasma cell leukemia.

Authors:  R E Tiedemann; N Gonzalez-Paz; R A Kyle; R Santana-Davila; T Price-Troska; S A Van Wier; W J Chng; R P Ketterling; M A Gertz; K Henderson; P R Greipp; A Dispenzieri; M Q Lacy; S V Rajkumar; P L Bergsagel; A K Stewart; R Fonseca
Journal:  Leukemia       Date:  2008-01-24       Impact factor: 11.528

Review 3.  Plasma cell leukemia: a highly aggressive monoclonal gammopathy with a very poor prognosis.

Authors:  Victor H Jimenez-Zepeda; Virginia J Dominguez-Martinez
Journal:  Int J Hematol       Date:  2009-03-27       Impact factor: 2.490

4.  A novel report of cig-FISH and cytogenetics in POEMS syndrome.

Authors:  Alan H Bryce; Rhett P Ketterling; Morie A Gertz; Martha Lacy; Ryan A Knudson; Shaji Kumar; Robert A Kyle; Rafael Fonseca; Phillip R Greipp; John A Lust; Vincent S Rajkumar; Suzanne R Hayman; Francis Buadi; Stephen J Russell; Stephen R Zeldenrust; Angela Dispenzieri
Journal:  Am J Hematol       Date:  2008-11       Impact factor: 10.047

5.  Molecular spectrum of TP53 mutations in plasma cell dyscrasias by next generation sequencing: an Italian cohort study and overview of the literature.

Authors:  Marta Lionetti; Marzia Barbieri; Martina Manzoni; Sonia Fabris; Cecilia Bandini; Katia Todoerti; Filomena Nozza; Davide Rossi; Pellegrino Musto; Luca Baldini; Antonino Neri
Journal:  Oncotarget       Date:  2016-04-19

6.  Natural history of multiple myeloma with de novo del(17p).

Authors:  Arjun Lakshman; Utkarsh Painuly; S Vincent Rajkumar; Rhett P Ketterling; Prashant Kapoor; Patricia T Greipp; Morie A Gertz; Francis K Buadi; Martha Q Lacy; David Dingli; Angela Dispenzieri; Amie L Fonder; Suzanne R Hayman; Miriam A Hobbs; Wilson I Gonsalves; Yi Lisa Hwa; Nelson Leung; Ronald S Go; Yi Lin; Taxiarchis V Kourelis; Rahma Warsame; John A Lust; Stephen J Russell; Steven R Zeldenrust; Robert A Kyle; Shaji K Kumar
Journal:  Blood Cancer J       Date:  2019-03-07       Impact factor: 11.037

7.  Deletions of CDKN2C in multiple myeloma: biological and clinical implications.

Authors:  Paola E Leone; Brian A Walker; Matthew W Jenner; Laura Chiecchio; Gianpaolo Dagrada; Rebecca K M Protheroe; David C Johnson; Nicholas J Dickens; Jose Luis Brito; Monica Else; David Gonzalez; Fiona M Ross; Selina Chen-Kiang; Faith E Davies; Gareth J Morgan
Journal:  Clin Cancer Res       Date:  2008-10-01       Impact factor: 12.531

8.  Novel tumor suppressor function of glucocorticoid-induced TNF receptor GITR in multiple myeloma.

Authors:  Yang Liu; Phong Quang; Esteban Braggio; Hai Ngo; Gayane Badalian-Very; Ludmila Flores; Yong Zhang; Antonio Sacco; Patricia Maiso; Abdel Kareem Azab; Feda Azab; Ruben Carrasco; Barrett J Rollins; Aldo M Roccaro; Irene M Ghobrial
Journal:  PLoS One       Date:  2013-06-13       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.